Urinary methylxanthine and autistic disorder: absence of previously reported correlation.
We were unable to reveal significant difference in the levels of xanthine and methylxanthines in the urine samples from 59 patients diagnosed with autistic symptoms and 64 age- and sex-matched normal volunteers. Our data suggest that abnormalities in xanthine and methylxanthine excretion (US Patent 20020019406 A1, Feb. 12, 2002) represent distincly uncommon symptoms in autism.
Salerno
C
C
Department of Gynecology, Perinatology and Child Health, University of Roma La Sapienza, Roma, Italy.
Crifò
C
C
D001321:Autistic Disorder / Q000652:urine*; D016022:Case-Control Studies; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006801:Humans; D008297:Male; D013053:Spectrophotometry; D013805:Theobromine / Q000652:urine; D013997:Time Factors; D014665:Vasodilator Agents / Q000652:urine; D014970:Xanthines / Q000652:urine*
D014665:Vasodilator Agents; D014970:Xanthines; C008514:methylxanthine; D013805:Theobromine